

Hyperbaric Oxygen Radiation Tissue Injury Study - III (Radiation cystitis)

Submission date 16/09/2008	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
Registration date 12/11/2008	Overall study status Stopped	<input type="checkbox"/> Protocol
Last Edited 18/01/2019	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Richard Clarke

Contact details
Baromedical Research Foundation
5 Richland Medical Park
Columbia
United States of America
29203
+1 803 434 7101
dick.clarke@palmettohealth.org

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00134628

Study information

Scientific Title
Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up

Acronym

HORTIS - III

Study objectives

The principle objective of this research is to more precisely determine the degree of benefit that hyperbaric oxygen therapy affords in the treatment of late radiation tissue injury.

The study has eight components. Seven involve evaluation of established radionecrosis at varying anatomic sites (mandible, larynx, skin, bladder, rectum, colon, and gynecology [GYN]). The eighth will investigate the potential of hyperbaric oxygen therapy to prophylax against late radiation tissue injury. This third study HORTIS-III will focus on patients with radiation cystitis.

This study will also generate more precise "Benchmarking" data as to the complications associated with hyperbaric exposure, including incidence and degree of morbidity.

Overview of the study can be found at: http://www.baromedicalresearch.org/pdf/HORTIS_Overview.pdf

All HORTIS trials that have been registered with ISRCTN can be found at: <http://www.controlled-trials.com/isrctn/search.html?srch=HORTIS&sort=3&dir=desc&max=10>

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the Palmetto Health, Richland IRB in 2002 (ref: 2002-17).

Study design

Double-blind randomised placebo-controlled multi-centre trial, with cross-over option

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Radiation cystitis

Interventions

Patients will be initially randomized to receive either oxygen at 2.0 atmospheres absolute (ATA), or air at 1.0 ATA.

The therapeutic algorithm is personalized to each patient's degree of response at specific points during their course of hyperbaric exposure. The total number of exposures will vary from between 20 and 40.

Following a 30-day observation/"wash out" period, the allocation assignment will be opened. Patients randomized to the 1.0 ATA air group will be offered the opportunity to cross-over to

the 2.0 ATA oxygen arm. The offer is mandatory, not so the requirement of the patient to cross-over. A therapeutic algorithm identical to the first randomization will be undertaken during any subsequent cross-over phase.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The following will be assessed at pre-treatment, 3 and 6 months, 1, 2, 3, 4 and 5 years post-treatment:

1. Subjective Objective Signs Management and Analysis/Late Effect of Normal Tissue (SOMA /LENT) scores
2. Clinical evaluation

Key secondary outcome(s)

Quality of Life, assessed by the Expanded Prostate Cancer Index Composite (EPIC) questionnaire at pre-treatment, 3 and 6 months, 1, 2, 3, 4 and 5 years post-treatment.

Completion date

21/07/2012

Reason abandoned (if study stopped)

Lack of funding/sponsorship

Eligibility

Key inclusion criteria

1. Both males and females between the ages of 18 and 70 years
2. Patients whose cancer treatment included radiotherapy and who have developed late radiation tissue injury, manifesting as one or more of the diagnostic criteria listed below:
 - 2.1. Endarteritis
 - 2.2. Hypocellularity
 - 2.3. Hypovascularity
 - 2.4. Vascular congestion
 - 2.5. Haemorrhage
 - 2.6. Necrosis
 - 2.7. Oedema
 - 2.8. Telangiectasis
 - 2.9. Urgency
 - 2.10. Pain
 - 2.11. Fistula
 - 2.12. Erythema
 - 2.13. Contracted bladder
 - 2.14. Dysplasia
 - 2.15. Vascularity ulceration
 - 2.16. Tissue hypoxia

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Reactive airway disease
2. Radiographic evidence of pulmonary blebs or bullae
3. Untreated pneumothorax
4. Previously documented ejection fraction less than 35%
5. History of seizures (except childhood febrile seizures)
6. Cardiovascular instability
7. Mechanical ventilator support
8. Unable to follow simple commands
9. Not orientated to person, place, time
10. Participating as a subject in any other medical or biomedical research project (if previously involved as a subject, sufficient time must have elapsed to permit "wash out" of any investigational agent)

Date of first enrolment

21/07/2003

Date of final enrolment

21/07/2012

Locations

Countries of recruitment

Australia

Mexico

South Africa

Türkiye

United States of America

Study participating centre

Baromedical Research Foundation
Columbia
United States of America
29203

Sponsor information

Organisation
Baromedical Research Foundation (USA)

Funder(s)

Funder type
Industry

Funder Name
National Baromedical Services, Inc (USA)

Funder Name
The Lotte and John Hecht Memorial Foundation (Canada)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results of one treatment arm	01/09/2008	18/01/2019	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes